An Open-Label Phase IIa Study Evaluating Trastuzumab/Pertuzumab, Erlotinib, Vemurafenib/Cobimetinib, Vismodegib, Alectinib, and Atezolizumab in Patients Who Have Advanced Solid Tumors with Mutations or Gene Expression Abnormalities Predictive of Response to One of These Agents

Protocol No
GENENTECH-MYPATHWAY
Principal Investigator
Ben George
Phase
II
Summary
Many cancers contain molecular abnormalities (cells show biological and genetic changes in the laboratory) that cause or contribute to their ability to grow and spread. By blocking the effects of these abnormalities, the growth of cancer may be stopped or slowed down. Many new cancer drugs work in this way. Because they block the effects of specific molecular abnormalities within the cancer, they are known as targeted agents. As more such targets are identified, and more drugs are found to work against them, more patients are now having molecular tests done on their tumor tissue or on blood ( molecular profiling ), in order to identify potential molecular targets for treatment.
Description
My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors
Participating Institutions
Froedtert Hospital
Status
OPEN TO ACCRUAL
Share This: